CN Patent

CN121591830A — 曲非奈肽的结晶形式

Assigned to Acadia Pharmaceuticals Inc · Expires 2026-03-03 · 0y expired

What this patent protects

本申请涉及曲非奈肽的结晶形式。本公开提供了：曲非奈肽和曲非奈肽水合物的结晶形式；包含曲非奈肽和曲非奈肽水合物的结晶形式的药物组合物；制备曲非奈肽或曲非奈肽水合物的结晶形式的方法；以及治疗受试者的疾病、病症或病状的方法，其包括向所述受试者施用包含曲非奈肽或曲非奈肽水合物的结晶形式的组合物。

USPTO Abstract

本申请涉及曲非奈肽的结晶形式。本公开提供了：曲非奈肽和曲非奈肽水合物的结晶形式；包含曲非奈肽和曲非奈肽水合物的结晶形式的药物组合物；制备曲非奈肽或曲非奈肽水合物的结晶形式的方法；以及治疗受试者的疾病、病症或病状的方法，其包括向所述受试者施用包含曲非奈肽或曲非奈肽水合物的结晶形式的组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN121591830A
Jurisdiction
CN
Classification
—
Expires
2026-03-03
Drug substance claim
No
Drug product claim
No
Assignee
Acadia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.